Both of these businesses prospered even during a volatile year -- and the coming months could be even more impressive.
News & Analysis: Fulgent Genetics, Inc.
These winners are positioned for gains even after COVID.
A Wall Street analyst downgraded the genetics testing provider.
Both of these stocks are up more than 300% in 2020 and have room to run.
Could this genetic testing provider turn its coronavirus bump into long-term share price growth?
Should you invest in shares of this high-flying coronavirus stock before it's too late?
The encore to a great 2019: Even more gains this year.
The COVID-19 pandemic continues to provide a tailwind for the genetic testing specialist.
Wall Street seems worried that the arrival of coronavirus vaccines will take the wind out of the sails of this genetic and medical testing company. That view misses the big picture.
Coronavirus testing demand caused revenue and profit to surge last quarter.